A study of the risk factors associated with bacteraemia in 191 allogeneic bone marrow transplant (BMT) recipients (1991-1996) was performed. In contrast to risk factors commonly cited for cancer chemotherapy, mucositis, degree of conditioning toxicity of the gut and lungs, duration of neutropenia, and severity of neutropenia and monocytopenia were not associated with bacteraemia in the pre-engraftment period, during which the only significant risk factor was late stage underlying disease (P Ͻ 0.05). After engraftment, Hickman catheter infection, and severe acute and chronic graft-versushost disease (GVHD) were found to be independently associated with bacteraemia by multivariate analysis (P Ͻ 0.001, Ͻ0.05 and Ͻ0.05, respectively). This might be explained by intense antimicrobial prophylaxis, early empirical treatment, and non-routine use of haemopoietic growth factors. No significant difference in mortality was detected between bacteraemic and non-bacteraemic patients in both periods. Allogeneic BMT recipients are therefore a group of patients distinct from other cancer patients receiving chemotherapy at risk of developing bacteraemia. The study findings prompt consideration of a management protocol incorporating early and routine use of haemopoietic growth factors before engraftment in high-risk patients with late stage underlying malignancies, routine antimicrobial prophylaxis for acute GVHD with intense immunosuppression, and intravenous immunoglobulin therapy for chronic GVHD. Further cost-benefit analyses are warranted.
Bacteraemia is one of the most serious infectious complications in patients undergoing chemoradiotherapy for malignant diseases. About 20% of patients with neutropenic fever have been documented to have this complication, which could be fatal without appropriate and expedient treatment. 1 The relationship between the incidence of bacteraemia and number of circulating neutrophils has been well studied in patients with acute leukemia receiving treatment. 2 Pizzo et al showed that infectious complications including bacteraemia occurred in a significant proportion of patients with granulocytopenia of more than 7 days duration after the discontinuation of a 7 day course of empirical antimicrobial chemotherapy for neutropenic fever. However, the authors were not able to define factors predicting bacteraemia at the onset of an episode of fever and neutropenia. 3 Furthermore, bacteraemic sepsis has been shown to be an important infectious complication even in the post-neutropenic period, 4 and prolonged neutropenia has been found to be a risk factor for the development of infectious complications in BMT recipients undergoing autologous or peripheral stem cell (PSC) transplant. 5 Bone marrow transplantation (BMT) is uniquely the most aggressive among the different forms of cancer therapy. Unlike the induction chemotherapy for solid tumours, lymphoma and leukemia, it is invariably associated with a longer duration of profound neutropenia (particularly in patients undergoing allogeneic transplant), a high level of prophylactic immunosuppression against graft-versus-host disease (GVHD) and severe conditioning-related toxicity. Despite the large amount of literature on bacterial infections and antimicrobial trials in BMT recipients, no comprehensive study on the risk factors predisposing to bacteraemia in such patients before and after engraftment has been published (MEDLINE search from . In the current study of 191 allogeneic BMT recipients, we describe 57 patients with 62 episodes of bacteraemia yielding 66 isolates within a follow-up period from day −7 to day 180. The risk factors for the development of symptomatic bacteraemia during different stages of the BMT, the outcome of patients and implications on prevention are analyzed and discussed.
Patients and methods

Patients and antimicrobial prophylaxis
One hundred and ninety-one patients (aged 17 or more) who underwent allogeneic BMT at Queen Mary Hospital in Hong Kong during a 6-year period (1991) (1992) (1993) (1994) (1995) (1996) were included in this study. All clinical and microbiological data before engraftment were collected prospectively by a registered nurse and a medical registrar. Between discharge after engraftment and day 180, the data were retrospectively collected by review of patients' records. Episodes of bacteraemia as a result of platelet transfusion were excluded from the study. 6 All isolates in polymicrobial bacteraemia, multiple episodes of bacteraemia and break-through bacterae-mia were included, but any patient with multiple isolates was counted only once in the statistical analysis for risk factors predisposing to bacteraemia.
All marrow cell inoculums were cultured before infusion. In addition, for ABO blood group mismatched transplants, the marrows had to undergo red cell depletion before infusing to the recipient. Before engraftment, all patients were kept in single isolation rooms equipped with high efficiency particulate air filtration. 7 From day 0 till stable engraftment, all patients were given chlorhexidene mouth washes, amphotericin B lozenges, oral ciprofloxacin (500 mg twice a day) and acyclovir (200 mg three times a day), and if oral medication could not be tolerated, i.v. ciprofloxacin 4 mg/kg every 12 h and i.v. acyclovir 5 mg/kg every 8 h were given. 8 From engraftment until day 100+, all patients received oral cotrimoxazole (960 mg three times a week). All patients were educated on the proper care of their Hickman catheters, flushing them weekly with heparin-saline when not in use.
Hospitalized patients were assessed daily and outpatients at least once weekly, for symptoms and signs of infection, treatment-related toxicity and GVHD. Organ imaging and clinical specimens for microbiological tests were done if clinically indicated. When patients developed neutropenic fever, blood cultures were taken and they were treated empirically with i.v. imipenem/cilastin (10 mg/kg every 6 h). If fever persisted for 48 h and the sepsis workup showed no positive findings, i.v. vancomycin (10 mg/kg every 6 h) was added. On the 5th day of unresponsive neutropenic fever, i.v. amphotericin B (0.5-1.0 mg/kg/day) was initiated. Blood cultures were repeated before any change of antimicrobials, and the antimicrobial regimen was modified according to any positive blood culture results.
All patients received the following as acute GVHD prophylaxis: i.v. methotrexate (15 mg/m 2 ) on day 1, (10 mg/m 2 ) on days 3, 6, 11; oral cyclosporin A (5 mg/kg twice a day) from day 1 to day 50 or i.v. cyclosporin A (1.5 mg/kg every 12 h) when the patient could not tolerate oral medication. Haemopoietic growth factors (G-CSF or GM-CSF) were commenced if engraftment failed by day 28. G-CSF was also used in patients with neutropenia secondary to ganciclovir therapy.
Microbiological methods
During the first episode of neutropenic fever, paired blood cultures were taken through the Hickman catheter and by percutaneous puncture. In subsequent episodes, blood cultures were obtained through the Hickman catheter twice, and through different lumens if multi-lumen catheters were in use. The BACTEC 660 and BACTEC 9240 blood culture system (Becton Dickinson, Sparks, MD, USA) was used in 1991-1995 and 1995-1996 , respectively. Each set of blood cultures consisted of an aerobic bottle with resin and an anaerobic bottle. All blood culture isolates were identified by standard biochemical methods, 9 and the identity of isolates was confirmed by the VITEK Automicrobic System (BioMerieux Vitek, Hazelwood, USA). Antimicrobial susceptibility was tested by the Kirby Bauer disk diffusion method and results interpreted according to the NCCLs criteria. 10 Stool was sent for isolation of Clostridium difficile using cycloserine cefoxitin fructose agar 11 and detection of cytotoxin by tissue culture assay whenever the patient developed diarrhea. Hickman catheters were removed when there was malfunction of the catheter, tunnel tract infection, or persistent fever with bacteraemia but no identifiable source of infection, and were sent for quantitative bacterial culture using the Maki method. 12 Cultures from other body sites were performed as dictated by clinical findings.
Fevers during the post-engraftment period were investigated in a similar manner. From engraftment to day 100, all patients were monitored weekly for CMV DNA in peripheral blood leucocytes by nested PCR. 13 Asymptomatic patients who were found positive on two consecutive occasions were given pre-emptive therapy with i.v. ganciclovir (5 mg/kg every 24 h).
Haematological methods
Daily full blood counts and white cell differentials were performed with Technicon H 2 (Miles Corporation, New York, NY, USA) or Coulter STKS (Coulter Electronics, Hialeah, FL, USA) automated analyzers. Peripheral blood smears were manually reviewed when there was significant morphological flagging or whenever indicated.
Definitions
The pre-engraftment period is defined as the period between the day of commencement of conditioning (day −7) and the day of stable engraftment (absolute neutrophil count Ͼ0.5 × 10 9 /l), while the post-engraftment period is the period after stable engraftment until day 180 post BMT. Fever is defined as either three oral temperatures of Ͼ38°C during a 24-h period or a single oral temperature of Ͼ38.5°C.
3 Risk groups of the underlying diseases were stratified as follows:
14 acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in first complete remission (CR1), chronic myeloid leukemia (CML) in chronic phase, lymphoma in CR1, myeloma in CR and severe aplastic anemia (SAA) in patients less than 25 years old with no prior immunosuppressive therapy were considered as good-risk diseases; any disease status other than the above were considered as poor-risk diseases. Mucositis, gut toxicity, liver toxicity, acute and chronic GVHD were defined and graded according to published papers. 15, 16 As for the significance of a blood culture isolate, when coagulase-negative staphylococci, Bacillus spp., or Corynebacterium spp. were isolated, they were considered as significant only when there were more than one positive blood culture obtained from the Hickman catheter, concomitant positive blood cultures from the Hickman catheter and peripheral venepuncture, or concomitant positive blood and catheter tip cultures.
Data analyses
A comparison of characteristics between BMT recipients with and without bacteraemia in the pre-engraftment and post-engraftment periods was performed to identify risk factors that were significantly associated with bacteraemia in these two periods.
2 test was used for categorical variables and the unpaired Student's t-test was used for continuous variables. P Ͻ 0.05 was considered as statistically significant. Univariate logistic analysis was performed to identify factors associated with bacteraemia. Based on the results of the univariate analysis, variables with P Ͻ 0.05 were included in a multivariate logistic analysis. The backward elimination method was used as a variable selection technique.
Results
In the pre-engraftment period, 31 patients (16%) developed bacteraemia. Among the 34 blood culture isolates (Table 1) , 22 (64%) were Gram-positive organisms and 12 (36%) Gram-negative organisms. Staphylococci, viridans streptocci and non-fermenters accounted for 25, 18 and 18% of the blood culture isolates respectively. Bacillus spp., one of the major causes of catheter-related sepsis, constituted 12% of the isolates. Enterococci (6%), Corynebacterium jeikeium (3%), Enterobacteriaceae (9%) and Aeromonas spp. (9%) were occasionally isolated. The dominance of Gram-positive isolates is similar to that reported in previous studies in BMT recipients. 17, 18 Only 56, 33 and 33% of the staphylococci, streptococci and non-fermenters, respectively, were sensitive to ciprofloxacin. Among the 33 episodes of bacteraemia, 23 (70%) were documented during the first episode of neutropenic fever, while 10 (30%) were documented when the patients were put on empirical intravenous antibiotics before engraftment. The only clinically and microbiologically documentable source of bacteraemia was infection of the Hickman catheter. One patient had Bacillus spp. bacteraemia during conditioning (day −3), and two others had methicillin-resistant Staphylococcus aureus Table 1 Blood culture isolates from allogeneic BMT recipients in the pre-engraftment period and their antibiotic sensitivity patterns and Bacillus spp. during the neutropenic period. All three episodes necessitated the removal of the catheters. Among the three bacteraemic patients who died before engraftment, two died within 3 days after the documentation of bacteraemia.
In the post-engraftment period, 26 patients (14%) developed bacteraemia. Among the 32 blood culture isolates (Table 2) , 24 ((75%) were Gram-positive organisms and eight (25%) Gram-negative organisms. Staphylococci and non-fermenters accounted for 47 and 16% of the blood culture isolates, respectively. Similar to the pre-engraftment period, Bacillus spp. constituted 13% of the isolates, while Streptococcus pneumoniae (3%), corynebacteria (6%)), propionibacteria (3%), Moraxella spp. (3%) and Enterobacteriaceae (9%) were occasionally isolated. In contrast to the isolates in the pre-engraftment period, 73 and 80% of staphylococci and non-fermenters were sensitive to ciprofloxacin, while 20, 25 and 20% of the staphylococci, Bacillus spp. and non-fermenters were resistant to cotrimoxazole. As for clinically and microbiologically identifiable source of bacteraemia, three patients had pneumonia due to Streptococcus pneumoniae, Klebsiella spp. and Pseudomonas aeruginosa, respectively. One patient with bacteraemia due to Streptococcus pneumoniae had associated pyogenic arthritis of the knee, while another had Salmonella enteritidis enterocolitis. One patient, who was on thalidomide for poorly controlled chronic GVHD, succumbed with pyomyositis of both legs and nine blood cultures positive for Staphylococcus aureus despite treatment with high dose i.v. cloxacillin and gentamicin. Documented Hickman catheter infection was found in 10 (38%) of the patients. Seven of them presented with rigors within 1 h after flushing of their Hickman catheters with heparin-saline. Among the 26 patients with bacteraemia, eight (31%) had neutropenia, of whom six (75%) were on pre-emptive ganciclovir therapy 
Pen = penicillin; Ery = erythromycin; Van = vanocomycin; Met = methicillin; Cf = cephalothin; Cip = ciprofloxacin; Sxt = cotrimoxazole; Gen = gentamicin; Amp = ampicillin; Imp = imipenem; Caz = ceftazidime. and two (25%) had relapse of disease. Among the six bacteraemic patients who died before day 180, two died within 3 days after the documentation of bacteraemia. The characteristics of allogeneic BMT recipients with and without bacteraemia in the pre-and post-engraftment period were compared and summarized in Tables 3 and 4 . Poor risk underlying disease, which was present in 68% of patients with bacteraemia in the pre-engraftment period, was the only risk factor identified to be associated with bacteraemia in this period (P Ͻ 0.05). On the other hand, Hickman catheter infection, severe acute and chronic GVHD, which were present in 38, 42 and 42% of patients with bacteraemia in the post-engraftment period, respectively, were found to be independently associated with bacteraemia in this period (P Ͻ 0.001, Ͻ0.05 and Ͻ0.05, respectively). There was no statistically significant difference in mortality between the bacteraemic and non-bacteraemic groups in both the pre-engraftment and post-engraftment periods.
Discussion
The presence of viable bacteria in the blood stream of a BMT recipient during the pre-engraftment period generally implies that the organism has traversed the mucosal or skin barrier and has survived the attack by submucosal tissue macrophages or the meagre number of circulating monocytes. Not surprisingly, previous studies and comments on neutropenic bacteraemia have often emphasized the importance of conditioning-related toxicity, mucositis, severity and duration of neutropenia, and most recently, severity of monocytopenia. [19] [20] [21] Most of these studies have been carried out on patients with solid tumours, lymphoma or leukemia undergoing chemotherapy when the duration of neutropenia varied between less than 7 and 14 days. There has been no comprehensive study in the literature confirming the link between these often-cited factors and bacteraemia in the setting of allogeneic BMT where patients had a longer duration of neutropenia. A prospective study in these aspects is expected to be revealing and meaningful.
The only significant risk factor associated with bacteraemia in the pre-engraftment period was poor-risk status of the underlying disease in these 191 patients. One likely explanation for this finding is that the total amount of chemoradiotherapy previously given to this group of patients is higher because of (1) multiple courses of chemotherapy before BMT and (2) the use of more intensive chemoradiotherapy for conditioning in view of the more chemoresistant diseases. As a result, the reserve of phagocytes in the submucosal tissue, liver, spleen, lung and bone marrow was likely to be more depleted than in patients with good-risk underlying diseases. It can thus be envisaged that with late stage diseases, bacteria have a relative survival advantage as they traverse the mucosa into tissues and subsequently into the patient's bloodstream.
Regarding other risk factors during the pre-engraftment period, although none were significantly associated with the occurrence of bacteraemia, trends could be detected which warrant closer examination and possibly further study. Analysis of the nature of underlying diseases showed a relative predominance of patients with AML (P = 0.14), ALL (P = 0.20) and lymphoma (P = 0.08) in the bacteraemic group, compared with a predominance of patients with CML (74% of whom were in the chronic phase, P = 0.07) and other diseases (mainly SAA and other solid tumours, P = 0.19) in the non-bacteraemic group. This finding can probably be accounted for by the fact that patients with Table 3 Characteristics of allogeneic BMT recipients with and without bacteraemia in the pre-engraftment period BMT = bone marrow transplant; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myeloid leukemia; TBI = total body irradiation; GVHD = graft-versus-host disease. a Two and 10 BMT recipients with and without bacteraemia, respectively, did not engraft, and hence were not included in the statistical analysis.
CML and SAA received less chemoradiotherapy, and hence had a better reserve of tissue phagocytes than those with AML, ALL and lymphoma.
Contrary to previous reports on non-BMT neutropenic cancer patients, 2, 3, 16 and another report on risk factors associated with infectious complications in autologous marrow and PSC transplant recipients, 5 the duration and severity of neutropenia and monocytopenia were not significantly Table 4 Characteristics of allogeneic BMT recipients with and without bacteraemia in the post-engraftment period BMT = bone marrow transplant; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myeloid leukemia; TBI = total body irradiation; GVHD = graft-versus-host disease. a Absolute neutrophil count Ͻ1.5 × 10 9 /l. b Twelve BMT recipients without bacteraemia did not engraft, and hence were not included in the statistical analysis. c Two and 31 BMT recipients with and without bacteraemia died before day 100 (ie before the possible development of chronic GVHD), and hence were not included in the statistical analysis. associated with bacteraemia in allogeneic BMT recipients in the pre-engraftment period. This might be explained by intense antimicrobial prophylaxis, early empirical treatment, and non-routine use of haemopoietic growth factors. Nevertheless, a trend towards a longer duration of neutropenia (P = 0.35) and lower absolute neutrophil (P = 0.33) and monocyte counts (P = 0.31) in bacteraemic patients could be detected. Unlike patients with solid tumours, lymphoma or leukemia undergoing induction chemotherapy, the absolute number of circulating neutrophils and monocytes often reached an extremely low value for a rather uniformly long duration after conditioning with high-dose chemoradiotherapy in both bacteraemic and non-bacteraemic allogeneic BMT recipients. Therefore it is not surprising that no statistically significant difference could be demonstrated for these parameters in allogeneic BMT recipients. Since autologous and PSC transplants are usually associated with a less intense chemotherapy and hence shorter duration of neutropenia (mean = 15.5 days in a recent study 5 ), it is not surprising that the duration of neutropenia was associated with the development of infectious complications in that study, but not associated with the bac-teraemia in our allogeneic BMT recipients (of whom the mean duration of neutropenia was 22.4 days).
As for the post-engraftment period up to day 180 post BMT, the risk factors for bacteraemia were also found to be unique. Although neutropenic bacteraemia could still occur, especially in the setting of ganciclovir-related myelotoxicity and disease relapse, the majority of bacteraemic episodes in our patients occurred during treatment for acute or chronic GVHD. Patients with acute or chronic GVHD are subjected to intense immunosuppressive therapy. In addition, patients with chronic GVHD have been found to have suboptimal serum opsonizing activity due to the associated hypogammaglobulinaemia, 22 as exemplified by both our cases of Streptococcus pneumoniae bacteraemia in patients with chronic GVHD. Besides concomitant GVHD, only Hickman catheter infection requiring removal was associated with bacteraemia in the post-engraftment period. This finding is not unexpected in view of the higher number of patient-days being studied in comparison with the preengraftment period. A striking observation was the clinical presentation of bacteraemia with the acute onset of fever and rigors following routine flushing of the Hickman catheter in 70% of these patients.
Clinically identifiable infective foci associated with bacteraemia which were subsequently documented microbiologically could be found in 10 and 58% of the bacteraemic patients in the pre-engraftment and post-engraftment periods, respectively. This finding is consistent with the availability of a larger number of white blood cells infiltrating the focus of infection and thus producing more discernable symptoms and signs of inflammation in the postengraftment period.
Previous studies have shown that the routine use of G-CSF following autologous marrow transplantation reduces hospital stay 23 whereas in allogeneic transplantation, it reduces the incidence of fever, infection and antibiotic usage. Therefore, the American Society of Clinical Oncology has recently recommended the routine use of haemopoietic growth factors in BMT. 24 However, the financial implication of those regimens have prohibited such practice in the majority of European BMT centres although the Eastern Cooperative Oncology Group has given a similar recommendation. 25 In the light of the resource implication and the absence of data showing improvement of mortality, findings in this study have identified a group of BMT recipients with poor-risk status of underlying disease who may benefit from the selective use of haemopoietic growth factors. As for the post-engraftment period, minimizing the potential for bacteraemia by modulating the risk factors documented in this study may only be feasible in the context of acute GVHD, during which prophylactic antibiotics can be given. The other two factors, namely chronic GVHD and Hickman catheter-associated infection, are not currently amenable to simple measures of intervention. With chronic GVHD and associated hypogammaglobulinaemia, replacement by intravenous immunoglobulin may improve the opsonising activity of the serum in these patients.
